US FDA, NIH support projects advancing regulatory science
This article was originally published in RAJ Devices
The US National Institutes of Health and the Food and Drug Administration have together committed financial support for four projects in regulatory science that are expected to better inform scientists and regulatory reviewers about medical product safety, and improve the evaluation and availability of new medical products to the community1.
You may also be interested in...
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.
The Australian health care products regulator is inviting feedback on proposed measures to clarify the boundary for software-based products that are captured under the regulatory framework for medical devices.
A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.